Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
about
Significance of MDR1 and multiple drug resistance in refractory human epileptic brainPharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsThe tumor microenvironment and strategies to improve drug distributionSplenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male ratsDrug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals.Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells.Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers.Clinical significance of ABCB1 genotyping in oncology.Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesDrug activity prediction using multiple-instance learning via joint instance and feature selectionDapagliflozin in patients with type 2 diabetes mellitus.Cytokine regulation of P-glycoprotein.Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.Determination of fexofenadine in Hank's balanced salt solution by high-performance liquid chromatography with ultraviolet detection: application to Caco-2 cell permeability studies.Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypesTherapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinicTransporters and their impact on drug disposition.Implementation of multiple-instance learning in drug activity prediction.Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.Pharmacogenetics of opioids.Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells.Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.Histamine, histamine receptors and antihistamines: new concepts.Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.Mechanisms and therapeutic potential of inhibiting drug efflux transporters.The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors.Cyclophosphamide metabolite inducing apoptosis in RLS mouse lymphosarcoma cells is a substrate for P-glycoprotein.Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivoIncreased ubiquitination of multidrug resistance 1 by ginsenoside Rd.P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics.Statins and phenytoin interact - a case history.The effect of P-glycoprotein on methadone hydrochloride flux in equine intestinal mucosa.Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects.
P2860
Q24804381-0AAD3477-413D-421B-B4ED-5B2D34080E8AQ26749524-F3D2CC72-B9AC-42AF-9E89-6BA594E49EE1Q28384148-37AE1EB0-3B72-431D-B267-D62B2762F738Q28570040-BD4EF723-21E1-408F-B20B-C1DAE0F45117Q33509452-714E23EA-BED1-43BE-9452-D505A393C130Q33567539-64BA9B82-3DB2-4E6A-8830-4F5866E42B22Q33820761-3BB4209B-DC2A-4C8C-BF9F-C3ACE0DE634FQ33951034-95A1601E-45E4-4313-839B-50119C63807FQ34569114-7BE9C2FD-69C9-417C-B646-39BE77F29ED2Q34657381-30F9B17C-D3D5-4E62-9CBA-17D2AE86B647Q35051379-3932107F-CAAC-4B58-B7F8-7298CC1FFD3CQ35064363-3C28ADFD-73E4-4755-BCE8-536AB0EDCDABQ35085030-3B8B9D6A-B6C8-4C46-9DCF-E3A4C64EF745Q35164664-2D85BB78-567E-42B0-A714-ECD21E11FA57Q35232517-84338E2E-8A4E-49A0-9D88-B15E7A9833E4Q35826139-93030D48-CFC1-4777-839F-0030222CC25AQ35826795-7B6AE996-20F2-440E-B233-1C38B812BF55Q36123304-8F5B5BDF-1FC1-4197-B0F6-93E3D9FA6CF5Q36227916-1D7BE8E5-2355-41A2-BD8D-DF496E2262AAQ36613874-7D4E14A7-5A5A-4A8A-BFC3-5D7F4364617EQ36752672-73910298-8AFA-49F7-9497-5115BD62612CQ37011590-9D421E4F-AD78-460C-80D4-69089FF31E6CQ37065797-CB50C69A-72D2-4F90-A0AF-8334E6698E62Q37266286-57E7E938-56EA-4EA3-B1DA-A121F2992F67Q37276411-6FAFD6DB-A0F2-45D0-909B-BEF77BDCA834Q37688480-721EBC0B-FE0A-4881-A037-1F7DC9D70824Q37762461-989D7EEB-6E3C-46C8-BD95-F10A3DF48F2BQ38099191-3AE67B6A-3211-41A2-9458-67F4317A0E8BQ38388828-C5FF8357-6457-44A9-B52B-20519F35B86FQ39196784-113AEA37-383B-4CFA-8479-2F500DED324EQ39302228-25B38A9D-FEF5-49E0-B232-EF9F9E7B4282Q39313291-372EDBCC-2BF9-4047-9A59-319E11A74161Q39636386-7E0A3C9E-187E-4FB0-BE23-C9FC2998C80EQ39748394-6A0C4C66-654D-46E2-8DB6-D33B00DD918AQ39905120-F4580665-7927-43C7-BFC1-FF71CB323471Q40121784-9FAB8C20-7C1D-4C5D-AE09-B648E669A65FQ40180361-A40824A8-1B32-4F57-A3FC-CDF6CF594D6CQ43110341-E433AF3F-7D0B-4314-8E42-9D77ABEF336CQ43943908-DC581B31-837C-427C-B90D-482C150907B1Q44571968-AC17B067-063D-4121-837B-8E0BBFDF9F88
P2860
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@ast
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@en
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@nl
type
label
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@ast
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@en
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@nl
prefLabel
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@ast
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@en
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.
@en
P2093
P2860
P304
P356
10.1592/PHCO.21.9.778.34558
P407
P577
2001-07-01T00:00:00Z